Tectonic Therapeutic, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Tectonic Therapeutic, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($74.15M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($57.98M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($42.82M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($105.89M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($119.13M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($119.71M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($72.97M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($46.36M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($18.65M) | Mar 25, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($84.04M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($58.02M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($44.65M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($105.43M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($118.84M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($120.23M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($75.81M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($46.24M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($18.39M) | Mar 25, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $63.49M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $41.36M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $36.97M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $72.19M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $83.11M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $87.24M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $54.97M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $35.10M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $15.19M | Mar 25, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($60.08M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($59.08M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($40.68M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($97.21M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($98.03M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($98.80M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($67.67M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($37.65M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($16.38M) | Mar 25, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $208.0K | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $156.0K | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $279.0K | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $267.0K | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $2.46M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $1.18M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $1.59M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $1.83M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $383.0K | Mar 25, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $261.04M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $152.91M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $39.40M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $103.95M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $203.84M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $271.23M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $200.51M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $133.48M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $7.02M | Mar 25, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.71M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $12.13M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $43.41M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $28.58M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $34.36M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $16.89M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $14.50M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $11.30M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $3.66M | Mar 25, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $251.33M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $140.78M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($84.64M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($45.65M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | $169.48M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $254.34M | Mar 23, 2023 |
| FY2021 | Dec 31, 2019 | $186.01M | Mar 17, 2022 |
| FY2020 | Dec 31, 2018 | $122.18M | Mar 18, 2021 |
| FY2019 | Dec 31, 2017 | ($23.14M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | ($4.58M) | Mar 25, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($222.74M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($148.59M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($90.60M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($489.43M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($383.54M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($264.42M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($144.70M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($71.74M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($23.47M) | Mar 25, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $253.80M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $141.24M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $28.77M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $92.56M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $189.57M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $259.68M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $187.04M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $126.30M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $5.96M | Mar 25, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $15.00M | Mar 23, 2023 |
| FY2021 | Dec 31, 2021 | $15.00M | Mar 17, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (6) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | (33) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 23, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (6) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | (33) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 23, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 18.74M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 14.86M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 1.41M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 43.92M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | 43.65M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | 43.65M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | 31.64M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | 23.81M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | 2.31M | Mar 25, 2019 |